Summary
The revised pricing will be effective from 9 November, following a Gazette notification issued on 17 October.
The move is intended to ease the financial burden of cancer treatment and ensure continued supply of these medicines.
Key Points
3 points1
The price cap applies to immunotherapies, denosumab, pegfilgrastim, bevacizumab and other widely used cancer drugs.
2
Manufacturers must inform the authority of new prices within seven days and display them publicly.
3
State drug controllers will monitor compliance by manufacturers, retailers, and hospitals.
New Words to Learn
9 wordsNational Pharmaceutical Pricing Authority
India's government body that regulates the prices of medicines
maximum retail price
the highest price a retailer is allowed to charge for a product
non‑scheduled medicines
drugs that are not listed under special government price controls
trade‑margin cap
a limit on the extra percentage a seller can add to the base price
immunotherapy
a type of treatment that helps the body's immune system fight cancer
denosumab
a medicine used for bone problems in breast and prostate cancer patients
pegfilgrastim
a drug that helps prevent low white‑blood‑cell counts during cancer treatment
bevacizumab
a medication used to treat several types of cancer such as colon, ovarian and cervical cancers
Gazette notification
an official public announcement published by the government
Want to learn even more? Click here to read the full story!
🔊 Reading Article
Kid-friendly voice